{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:59:29Z","timestamp":1768003169581,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:p>Das Prostatakarzinom (PC) ist die zweith\u00e4ufigste Krebserkrankung bei M\u00e4nnern. Sobald die Krankheit auf eine Androgenentzugstherapie nicht mehr anspricht, sind die verbleibenden Behandlungsoptionen begrenzt. Trotz intensiver Bem\u00fchungen konnte bislang nur wenige der T\u2011Zell-basierten immuntherapeutischen Strategien, die mittlerweile bei der Behandlung anderer Krebserkrankungen etabliert sind, f\u00fcr das PC erfolgreich implementiert werden. Dies gilt sowohl f\u00fcr die Immun-Checkpoint-Inhibition, welche die T\u2011Zell-Immunit\u00e4t generell verst\u00e4rkt, jedoch bislang keine \u00fcberzeugenden Ergebnisse erbracht hat, als auch f\u00fcr chim\u00e4re Antigenrezeptor\u2011T (CART)-Zellen und bispezifische Antik\u00f6rper (bsAbs), die T\u2011Zellen gezielt gegen Tumorzellen mobilisieren. Im Vergleich zu CART-Zellen bieten bsAbs den Vorteil, dass sie als \u201eOff the shelf\u201c-Reagenzien unmittelbar verf\u00fcgbar sind, was eine Therapieverz\u00f6gerung vermeidet und mit geringerem Kostenaufwand verbunden ist. Aktuell befinden sich mehrere bsAbs zur Behandlung des PC in Entwicklung. W\u00e4hrend einige Pr\u00e4parate aufgrund von Nebenwirkungen und Anti-drug-antibody-Bildung mittlerweile nicht mehr weiterverfolgt werden, haben andere vielversprechende erste Ergebnisse geliefert. Hierzu geh\u00f6ren insbesondere gegen STEAP1 und gegen PSMA gerichtete bsAbs, die mittlerweile neben der metastasierten Situation auch im biochemischen Rezidiv evaluiert werden. Die zugrundeliegenden Konzepte sowie der aktuelle Stand der klinischen Entwicklung, sowie die zuk\u00fcnftigen Perspektiven werden dargestellt und diskutiert.<\/jats:p>","DOI":"10.1007\/s00120-025-02574-w","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T07:27:04Z","timestamp":1743751624000},"page":"933-939","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bispezifische Antik\u00f6rper in der Therapie des Prostatakarzinoms","Bispecific antibodies in prostate cancer therapy"],"prefix":"10.1007","volume":"64","author":[{"given":"Susanne","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Heitmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Pfl\u00fcgler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gundram","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Salih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"2574_CR1","doi-asserted-by":"crossref","unstructured":"Agarwal N, Azad A, Carles J et\u00a0al (2024) CONTACT-02: Phase\u00a03\u00a0study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). JCO 42:","DOI":"10.1200\/JCO.2024.42.4_suppl.18"},{"key":"2574_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray\u00a0F, Laversanne\u00a0M, Sung\u00a0H et\u00a0al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"2574_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","volume":"9","author":"U Brinkmann","year":"2017","unstructured":"Brinkmann\u00a0U, Kontermann\u00a0RE (2017) The making of bispecific antibodies. MAbs 9:182\u2013212","journal-title":"MAbs"},{"key":"2574_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/MOU.0000000000000776","volume":"30","author":"S Bronimann","year":"2020","unstructured":"Bronimann\u00a0S, Lemberger\u00a0U, Bruchbacher\u00a0A et\u00a0al (2020) Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer. Curr Opin Urol 30:519\u2013526","journal-title":"Curr Opin Urol"},{"key":"2574_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford\u00a0P, Van Den Bergh\u00a0RCN, Briers\u00a0E et\u00a0al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I:\u00a0Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 86:148\u2013163","journal-title":"Eur Urol"},{"key":"2574_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS De Bono","year":"2010","unstructured":"De Bono\u00a0JS, Oudard\u00a0S, Ozguroglu\u00a0M et\u00a0al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a\u00a0randomised open-label trial. Lancet 376:1147\u20131154","journal-title":"Lancet"},{"key":"2574_CR7","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-20-3725","volume":"27","author":"P Deegen","year":"2021","unstructured":"Deegen\u00a0P, Thomas\u00a0O, Nolan-Stevaux\u00a0O et\u00a0al (2021) The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res 27:2928\u20132937","journal-title":"Clin Cancer Res"},{"key":"2574_CR8","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten\u00a0JH, Helou\u00a0YA, Chopra\u00a0G et\u00a0al (2016) CD28 Costimulation: From Mechanism to Therapy. Immunity 44:973\u2013988","journal-title":"Immunity"},{"key":"2574_CR9","volume-title":"2024 ASCO Annual Meeting","author":"G Falchook","year":"2024","unstructured":"Falchook\u00a0G et\u00a0al (2024) Phase\u00a01 clinical trial of AMG 340, a\u00a0prostate-specific membrane antigen (PSMA)-targeted T\u2011cell engager with a\u00a0novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC). In: 2024 ASCO Annual Meeting. Chicago"},{"key":"2574_CR10","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.4049\/jimmunol.1200341","volume":"189","author":"A Feldmann","year":"2012","unstructured":"Feldmann\u00a0A, Arndt\u00a0C, Topfer\u00a0K et\u00a0al (2012) Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T\u00a0cells. J\u00a0Immunol 189:3249\u20133259","journal-title":"J Immunol"},{"key":"2574_CR11","doi-asserted-by":"crossref","unstructured":"Heitmann J et\u00a0al Updated results on the bispecific PSMAxCD3 antibody CC\u20111 for treatment of prostate cancer. JCO 42:","DOI":"10.1200\/JCO.2024.42.16_suppl.2536"},{"key":"2574_CR12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman\u00a0MS, Emmett\u00a0L, Sandhu\u00a0S et\u00a0al (2021) (177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a\u00a0randomised, open-label, phase\u00a02\u00a0trial. Lancet 397:797\u2013804","journal-title":"Lancet"},{"key":"2574_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/imt-2020-0256","volume":"13","author":"HD Hummel","year":"2021","unstructured":"Hummel\u00a0HD, Kufer\u00a0P, Grullich\u00a0C et\u00a0al (2021) Pasotuxizumab, a\u00a0BiTE((R)) immune therapy for castration-resistant prostate cancer: Phase\u00a0I, dose-escalation study findings. Immunotherapy 13:125\u2013141","journal-title":"Immunotherapy"},{"key":"2574_CR14","first-page":"1807","volume":"54","author":"RS Israeli","year":"1994","unstructured":"Israeli\u00a0RS, Powell\u00a0CT, Corr\u00a0JG et\u00a0al (1994) Expression of the prostate-specific membrane antigen. Cancer Res 54:1807\u20131811","journal-title":"Cancer Res"},{"key":"2574_CR15","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1126\/science.359.6382.1344","volume":"359","author":"PN Kelly","year":"2018","unstructured":"Kelly\u00a0PN (2018) The Cancer Immunotherapy Revolution. Science 359:1344\u20131345","journal-title":"Science"},{"key":"2574_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","volume":"14","author":"WK Kelly","year":"2024","unstructured":"Kelly\u00a0WK, Danila\u00a0DC, Lin\u00a0CC et\u00a0al (2024) Xaluritamig, a\u00a0STEAP1 x CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a\u00a0First-in-Human Study. Cancer Discov 14:76\u201389","journal-title":"Cancer Discov"},{"key":"2574_CR17","doi-asserted-by":"crossref","unstructured":"Kim TJ, Koo KC (2020) Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A\u00a0Comprehensive Review. Int J Mol Sci 21:","DOI":"10.3390\/ijms21155484"},{"key":"2574_CR18","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby\u00a0M, Hirst\u00a0C, Crawford\u00a0ED (2011) Characterising the castration-resistant prostate cancer population: a\u00a0systematic review. Int J Clin Pract 65:1180\u20131192","journal-title":"Int J Clin Pract"},{"key":"2574_CR19","doi-asserted-by":"publisher","first-page":"1285661","DOI":"10.3389\/fonc.2023.1285661","volume":"13","author":"H Nakamura","year":"2023","unstructured":"Nakamura\u00a0H, Arihara\u00a0Y, Takada\u00a0K (2023) Targeting STEAP1 as an anticancer strategy. Front Oncol 13:1285661","journal-title":"Front Oncol"},{"key":"2574_CR20","doi-asserted-by":"publisher","first-page":"2356820","DOI":"10.1080\/15384047.2024.2356820","volume":"25","author":"J Palecki","year":"2024","unstructured":"Palecki\u00a0J, Bhasin\u00a0A, Bernstein\u00a0A et\u00a0al (2024) T\u2011Cell redirecting bispecific antibodies: a\u00a0review of a\u00a0novel class of immuno-oncology for advanced prostate cancer. Cancer Biol Ther 25:2356820","journal-title":"Cancer Biol Ther"},{"key":"2574_CR21","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41585-023-00739-w","volume":"20","author":"I Rastogi","year":"2023","unstructured":"Rastogi\u00a0I, Muralidhar\u00a0A, Mcneel\u00a0DG (2023) Vaccines as treatments for prostate cancer. Nat Rev Urol 20:544\u2013559","journal-title":"Nat Rev Urol"},{"key":"2574_CR22","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.4161\/hv.29553","volume":"10","author":"S Rausch","year":"2014","unstructured":"Rausch\u00a0S, Schwentner\u00a0C, Stenzl\u00a0A et\u00a0al (2014) mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum Vaccin Immunother 10:3146\u20133152","journal-title":"Hum Vaccin Immunother"},{"key":"2574_CR23","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3389\/fimmu.2020.01109","volume":"11","author":"A Rodriguez-Garcia","year":"2020","unstructured":"Rodriguez-Garcia\u00a0A, Palazon\u00a0A, Noguera-Ortega\u00a0E et\u00a0al (2020) CAR\u2011T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. Front Immunol 11:1109","journal-title":"Front Immunol"},{"key":"2574_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","volume":"18","author":"SP Rowe","year":"2016","unstructured":"Rowe\u00a0SP, Macura\u00a0KJ, Mena\u00a0E et\u00a0al (2016) PSMA-Based [(18)F]DCFPyL PET\/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Mol Imaging Biol 18:411\u2013419","journal-title":"Mol Imaging Biol"},{"key":"2574_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003518","author":"N Shore","year":"2023","unstructured":"Shore\u00a0N et\u00a0al (2023) LBA02-09 EMBARK: A\u00a0Phase\u00a03 Randomized Study Of Enzalutamide Or Placebo Plus Leuprolide Acetate And Enzalutamide Monotherapy In High-Risk Biochemically Recurrent Prostate Cancer. J\u00a0Clin Urol. https:\/\/doi.org\/10.1097\/JU.0000000000003518","journal-title":"J Clin Urol"},{"key":"2574_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1200\/JCO.2023.41.6_suppl.154","volume":"41","author":"M Stein","year":"2023","unstructured":"Stein\u00a0M et\u00a0al (2023) Preliminary results from a\u00a0phase\u00a01\/2\u00a0study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J\u00a0Clin Oncol 41:154","journal-title":"J Clin Oncol"},{"key":"2574_CR27","doi-asserted-by":"publisher","first-page":"285193","DOI":"10.1155\/2015\/285193","volume":"2015","author":"U Vaishampayan","year":"2015","unstructured":"Vaishampayan\u00a0U, Thakur\u00a0A, Rathore\u00a0R et\u00a0al (2015) Phase\u00a0I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients. Prostate Cancer 2015:285193","journal-title":"Prostate Cancer"},{"key":"2574_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1042\/BJ20120433","volume":"445","author":"K Yamamoto","year":"2012","unstructured":"Yamamoto\u00a0K, Trad\u00a0A, Baumgart\u00a0A et\u00a0al (2012) A novel bispecific single-chain antibody for ADAM17 and CD3 induces T\u2011cell-mediated lysis of prostate cancer cells. Biochem\u00a0J 445:135\u2013144","journal-title":"Biochem J"},{"key":"2574_CR29","doi-asserted-by":"publisher","first-page":"e11902","DOI":"10.15252\/emmm.201911902","volume":"13","author":"L Zekri","year":"2021","unstructured":"Zekri\u00a0L, Vogt\u00a0F, Osburg\u00a0L et\u00a0al (2021) An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer. EMBO Mol Med 13:e11902","journal-title":"EMBO Mol Med"},{"key":"2574_CR30","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s10637-018-0683-9","volume":"37","author":"H Zhao","year":"2019","unstructured":"Zhao\u00a0H, Ma\u00a0J, Lei\u00a0T et\u00a0al (2019) The bispecific anti-CD3 x anti-CD155 antibody mediates T\u00a0cell immunotherapy for human prostate cancer. Invest New Drugs 37:810\u2013817","journal-title":"Invest New Drugs"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02574-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02574-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02574-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T10:03:45Z","timestamp":1757153025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02574-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2574"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02574-w","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"10 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G. Jung und H. Salih sind auf den Patenten PCT\/EP2027\/050834, EP16151281.9, CN108699157B, WO2017\/121905, US11612646B2 (PSMA Binding Antibody And Uses Thereof) als Erfinder aufgef\u00fchrt. S.\u00a0Jung, J.\u00a0Heitmann M.\u00a0Pfl\u00fcgler und S.\u00a0Rausch geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}